Curated News
By: NewsRamp Editorial Staff
September 03, 2026
BioVersys to Present at Major Investment Conference
TLDR
- BioVersys presents at H.C. Wainwright conference to attract investors for its MDR bacteria treatments, gaining competitive edge.
- BioVersys AG will present corporate overview and on-demand webcast at H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026.
- BioVersys advances novel antibacterial treatments for deadly resistant infections, aiming to save lives and improve global health.
- Learn about BioVersys's two technology platforms and Phase 3 candidate for Acinetobacter baumannii at the conference.
Impact - Why it Matters
This news matters because BioVersys is at the forefront of combating antimicrobial resistance (AMR), a global health crisis that threatens to render current antibiotics ineffective. Their participation in a major investment conference signals potential funding and partnerships that could accelerate the development of critical new treatments for drug-resistant infections, which directly impacts patients, healthcare systems, and global public health. By advancing therapies for infections like Acinetobacter baumannii and tuberculosis, BioVersys aims to fill a critical void in the antibiotic pipeline, offering hope for better outcomes and reduced mortality from resistant infections.
Summary
BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, is set to showcase its innovative antibacterial pipeline at the prestigious H.C. Wainwright 28th Annual Global Investment Conference in New York City from September 14-16, 2026. The company's Chief Financial Officer, Hernan Levett, will deliver a corporate overview on September 16 at 12:30 PM ET in the Kennedy II room at the Lotte New York Palace. Additionally, CEO Dr. Marc Gitzinger will present an on-demand session available from September 11, accessible via the H.C. Wainwright Platform or the BioVersys website investor section. This participation underscores BioVersys's commitment to advancing novel antibacterial treatments for life-threatening infections caused by multi-drug resistant (MDR) bacteria.
BioVersys leverages two proprietary technology platforms—TRIC and Ansamycin Chemistry—to develop candidates that overcome resistance mechanisms, block virulence production, and directly target pathogenic bacteria. Their lead program, BV100, is in Phase 3 for nosocomial Acinetobacter baumannii infections, while alpibectir is in Phase 2 for tuberculosis in collaboration with GlaxoSmithKline and a consortium from the University of Lille, France. With a focus on addressing high unmet medical needs, BioVersys aims to provide new treatment options in the antimicrobial and microbiome fields. The original announcement was made via NEWMEDIAWIRE, and the full release is available on www.newmediawire.com.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, BioVersys to Present at Major Investment Conference
